Journal
DIABETES OBESITY & METABOLISM
Volume 14, Issue 2, Pages 130-138Publisher
WILEY
DOI: 10.1111/j.1463-1326.2011.01496.x
Keywords
insulin secretagogues; ischaemic preconditioning; sulfonylurea receptor
Categories
Funding
- Canadian Diabetes Association [OG-2-09-2693-SS]
- Blanch/Wirtanen/Alberta Diabetes Foundation/Alberta Diabetes Institute
- Alliance for Canadian Health Outcomes Research in Diabetes (ACHORD)
- Heart and Stroke Foundation of Canada
- Canadian Institutes of Health Research
Ask authors/readers for more resources
Aim: Insulin secretagogues promote insulin release by binding to sulfonylurea receptors on pancreatic beta-cells (SUR1). However, these drugs also bind to receptor isoforms on cardiac myocytes (SUR2A) and vascular smooth muscle (SUR2B). Binding to SUR2A/SUR2B may inhibit ischaemic preconditioning, an endogenous protective mechanism enabling cardiac tissue to survive periods of ischaemia. This study was designed to identify insulin secretagogues that selectively bind to SUR1 when given at therapeutic doses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
